X4 Pharmaceuticals, Inc.
XFOR
$3.59
$0.092.43%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -90.14M | -99.72M | -79.20M | -95.10M | -101.98M |
| Total Depreciation and Amortization | 1.67M | 1.02M | 1.28M | 1.33M | 1.37M |
| Total Amortization of Deferred Charges | 897.00K | 870.00K | 865.00K | 859.00K | 832.00K |
| Total Other Non-Cash Items | 10.09M | 6.69M | -5.99M | -3.28M | -1.57M |
| Change in Net Operating Assets | -6.25M | -1.71M | -2.58M | -6.90M | -7.95M |
| Cash from Operations | -83.74M | -92.85M | -85.62M | -103.09M | -109.30M |
| Capital Expenditure | -- | -- | -- | -41.00K | -133.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | 0.00 | 0.00 |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 6.43M | 30.54M | 8.15M | -17.28M | -4.44M |
| Cash from Investing | 6.43M | 30.54M | 8.15M | -17.32M | -4.58M |
| Total Debt Issued | -- | -- | -- | 0.00 | 0.00 |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 233.07M | 238.63M | 238.63M | 92.67M | 5.77M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 233.07M | 238.63M | 238.63M | 92.67M | 5.77M |
| Foreign Exchange rate Adjustments | -23.00K | 121.00K | 213.00K | -34.00K | 132.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 155.75M | 176.45M | 161.38M | -27.77M | -107.97M |